CN102861049B - Application of Houttuynoid A in medicine for treating liver cancer - Google Patents
Application of Houttuynoid A in medicine for treating liver cancer Download PDFInfo
- Publication number
- CN102861049B CN102861049B CN 201210417896 CN201210417896A CN102861049B CN 102861049 B CN102861049 B CN 102861049B CN 201210417896 CN201210417896 CN 201210417896 CN 201210417896 A CN201210417896 A CN 201210417896A CN 102861049 B CN102861049 B CN 102861049B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- liver cancer
- medicine
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 15
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 15
- FHNVKCJCSKWUFS-YLUJEXTNSA-N 4-[5,7-dihydroxy-4-oxo-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-yl]-7-hydroxy-2-nonyl-1-benzofuran-3-carbaldehyde Chemical compound C=12C(C=O)=C(CCCCCCCCC)OC2=C(O)C=CC=1C=1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FHNVKCJCSKWUFS-YLUJEXTNSA-N 0.000 title abstract description 40
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- 229930190556 houttuynoid Natural products 0.000 claims description 4
- 230000012010 growth Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid A in preparing a medicine for treating liver cancer, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTT method, Houttuynoid A has an obvious inhibiting effect on the growth of human liver cancer cell strains HepG2, MHCC-LM3, Be1-7402 and HuH-7. Therefore, Houttuynoid A can be used for preparing the medicine for preventing liver cancer, and has a favorable development and application prospect. The application of the Houttuynoid A in preparing the medicine for treating liver cancer, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid A to liver cancer cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid A, relate in particular to the application of Houttuynoid A in the preparation medicines resistant to liver cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) new framework compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes in preparation treatment liver-cancer medicine that the present invention relates to, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for hepatocarcinoma simultaneously obviously has obvious improvement.
Summary of the invention
The invention provides the application of compound H outtuynoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the preparation medicines resistant to liver cancer, and the structural formula of Houttuynoid A is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation the growth of the human hepatoma cell strain HepG2 of Houttuynoid A, MHCC-LM3, Bel-7402 and HuH-7 also has significant inhibitory effect, suppresses the IC of this 4 strain cell growth
50Value is respectively 8.29 ± 0.77 μ M, 7.49 ± 0.89 μ M, 6.44 ± 0.61 μ M and 10.22 ± 1.55 μ M.Therefore, Houttuynoid A can have the excellent development application prospect for the preparation of medicines resistant to liver cancer.
The present invention relates to the purposes of Houttuynoid A in preparation treatment liver-cancer medicine and belong to open first, because framework types belongs to brand-new framework types, and its inhibition for hepatoma carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for hepatocarcinoma simultaneously obviously has obvious improvement.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of the human hepatoma cell strain of mtt assay assessing compound Houttuynoid A
1. method: the cell that is in the growth logarithmic (log) phase: human hepatoma cell strain HepG2, MHCC-LM3, Bel-7402 and HuH-7(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Cell culture 24 h inhale adherent back and go original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, inhale along culture fluid top then and remove 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: the growth of the human hepatoma cell strain HepG2 of Houttuynoid A, MHCC-LM3, Bel-7402 and HuH-7 has significant inhibitory effect.This chemical compound suppresses the IC of human hepatoma cell strain HepG2, MHCC-LM3, Bel-7402 and HuH-7 growth
50Value is respectively: 8.29 ± 0.77 μ M, 7.49 ± 0.89 μ M, 6.44 ± 0.61 μ M and 10.22 ± 1.55 μ M.
Shown that by above-described embodiment the growth of the human hepatoma cell strain HepG2 of Houttuynoid A of the present invention, MHCC-LM3, Bel-7402 and HuH-7 has the good restraining effect.Prove that thus Houttuynoid A of the present invention has resisting liver cancer activity, can be for the preparation of medicines resistant to liver cancer.
Claims (1)
1.Houttuynoid the application of A in preparation treatment liver-cancer medicine, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210417896 CN102861049B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210417896 CN102861049B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861049A CN102861049A (en) | 2013-01-09 |
| CN102861049B true CN102861049B (en) | 2013-08-28 |
Family
ID=47440367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210417896 Expired - Fee Related CN102861049B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861049B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135445A1 (en) * | 2003-02-04 | 2006-06-22 | Kabushiki Kaisha Yakult Honsha | Breast cancer-resistant protein inhibitor |
-
2012
- 2012-10-27 CN CN 201210417896 patent/CN102861049B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861049A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861065B (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102861049B (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102861089B (en) | Application of Houttuynoid B in medicine for treating liver cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102861058B (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872069B (en) | Application of Houttuynoid C to preparing drugs for treating liver cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102861064B (en) | Application of Houttuynoid E in preparing medicine for treating laryngocarcinoma | |
| CN102861069B (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861061B (en) | Application of Houttuynoid B in cholangiocarcinoma treatment medicine | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU DINGBANG BIOMASS ENERGY MACHINERY CO., LTD Free format text: FORMER OWNER: WU JUNHUA Effective date: 20131209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 213351 CHANGZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131209 Address after: 213351 Jiangsu city of Changzhou province Liyang Liyang Town of Wuhu Shanghai Road No. 168 Patentee after: Jiangsu Dingbang Biomass Energy Machinery Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |